Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**AlphaBRAIN** is a dietary supplement marketed as a nootropic for supporting cognitive functions such as memory, focus, and mental processing speed[1][4][5]. Developed and manufactured by Onnit, AlphaBRAIN consists of a blend of vitamins, herbs, and amino acids, divided into proprietary blends targeting different putative mechanisms: enhancement of *acetylcholine* levels, promotion of *alpha brain wave* production, and support for nervous system communication[1][2][4]. Notably, it contains no caffeine. Key ingredients include Vitamin B6, alpha-GPC, Bacopa monnieri, Huperzia serrata (source of huperzine A, an acetylcholinesterase inhibitor), oat straw extract, L-tyrosine, L-theanine, phosphatidylserine, cat’s claw extract, L-leucine, vinpocetine, and pterostilbene. AlphaBRAIN is not approved as a pharmaceutical and is sold as a dietary supplement. The exact efficacy and safety profile remains uncertain due to underdisclosed dosages and limited independent research[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AlphaBRAIN.